Kringle Pharma Income Statement

Financials in millions JPY. Fiscal year is October - September.

Millions JPY. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Mar '25 Mar 31, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021	Sep '20 Sep 30, 2020	2018 - 2019
Revenue	72	80	69	391	289	467	Upgrade
Revenue Growth (YoY)	-7.69%	15.94%	-82.35%	35.29%	-38.12%	-	Upgrade
Cost of Revenue	-	-	-	88	71	-	Upgrade
Gross Profit	72	80	69	303	218	467	Upgrade
Selling, General & Admin	392	254	242	196	178	150	Upgrade
Research & Development	643	643	716	533	398	489	Upgrade
Operating Expenses	1,035	897	958	729	576	639	Upgrade
Operating Income	-963	-817	-889	-426	-358	-172	Upgrade
Currency Exchange Gain (Loss)	-	-	-	21	-1	-	Upgrade
Other Non Operating Income (Expenses)	62	62	36	75	59	56	Upgrade
Pretax Income	-901	-755	-853	-330	-300	-116	Upgrade
Income Tax Expense	1	1	1	1	1	1	Upgrade
Net Income	-902	-756	-854	-331	-301	-117	Upgrade
Net Income to Common	-902	-756	-854	-331	-301	-117	Upgrade
Shares Outstanding (Basic)	7	6	5	5	4	0	Upgrade
Shares Outstanding (Diluted)	7	6	5	5	4	0	Upgrade
Shares Change (YoY)	17.90%	18.72%	11.00%	16.91%	7422.44%	-94.70%	Upgrade
EPS (Basic)	-133.28	-118.14	-158.44	-68.16	-72.47	-2118.95	Upgrade
EPS (Diluted)	-133.28	-118.14	-158.44	-68.16	-72.47	-2118.95	Upgrade
Gross Margin	100.00%	100.00%	100.00%	77.49%	75.43%	100.00%	Upgrade
Operating Margin	-1337.50%	-1021.25%	-1288.41%	-108.95%	-123.88%	-36.83%	Upgrade
Profit Margin	-1252.78%	-945.00%	-1237.68%	-84.66%	-104.15%	-25.05%	Upgrade
EBIT	-963	-817	-889	-426	-358	-172	Upgrade
EBIT Margin	-	-	-	-108.95%	-123.88%	-36.83%	Upgrade

Updated Feb 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.